Research Article
Circulating Cytokines and Growth Factors in Pediatric Pulmonary Hypertension
Table 1
Patient demographics and clinical measurements.
| | Patient demographics (no of subjects = 70) | |
| | Female—no. (%) | 37 (52.9%) | | APAH—no. (%) | 45 (64.3%) | | Congential heart disease | 31 (44.3%) | | Chronic lung disease | 11 (15.7%) | | Clotting disorders | 10 (14.3%) | | Age (years)—median (IQR) | 8.0 (4.4–13.0) | | Therapies | | | Mono therapy | 23 (32.9%) | | Dual therapy | 23 (32.9%) | | Triple therapy | 10 (14.3%) | | Calcium channel blockers | 22 (31.4%) | | PDE-5 inhibitors | 29 (41.4%) | | Endothelin receptor blockers | 25 (35.7%) | | Prostacyclin | 23 (32.9%) | | Epoprostenol
| 12 (17.1%) | | IV Treprostinil
| 8 (11.4%) | | Inh Iloprost
| 3 (4.3%) | | CATH variables—median (IQR) (n = 59) | | | Pulmonary artery pressure, mm Hg | 34 (23–56) | | Pulmonary capillary wedge pressure, mm Hg | 8 (6–10) | | Right atrial pressure, mm Hg | 5 (3–7) | | Cardiac index, L/min × m2 | 3.5 (3.0–4.3) | | Pulmonary vascular resistance index, wood units × m2 | 5.6 (4.1–13.9) | | PVR/SVR | 0.48 (0.27–0.76) | | Vasoreactivity (% change in mPAP w/NO) | −21.1 (−29.5 to −12.8) | | Follow-up time (months)—median (min–max) | 36 (12–89) | | Adverse outcomes | 16 (22.9%) | | Within 12 months | 9 (12.9%) | | First observed outcome | | | Expired | 10 | | Transplantation | 0 | | Initiation of IV prostanoids | 8 |
|
|
